The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma
- PMID: 28262585
- DOI: 10.1016/j.ejca.2017.01.031
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma
Abstract
Aim: To investigate the histological subtypes of oesophageal adenocarcinoma according to the Laurén classification (intestinal/diffuse/mixed) in relation to tumour response to neoadjuvant treatment, and in relation to patients' survival after potentially curative treatment.
Methods: Data were collected from all oesophageal adenocarcinoma patients who underwent potentially curative treatment in our institute between 1998 and 2014. Treatment consisted of neoadjuvant chemoradiotherapy (36-50 Gy) followed by an oesophagectomy or definitive chemoradiotherapy (50-50.4 Gy). Clinical data were collected from patient records. All endoscopic biopsies and surgical resection specimens were reassessed to determine the histological subtype (intestinal, diffuse or mixed) and the Mandard tumour regression grade (TRG). The impact of the histological subtypes on survival was determined using a Cox model.
Results: Median follow-up was 68 months. Diffuse and mixed type cancers accounted for 25% of oesophageal adenocarcinomas. Median overall survival differed significantly between patients with intestinal (n = 121, 39 months), diffuse (n = 28, 18 months) or mixed type (n = 11, 25 months) carcinomas (log rank, p = 0.023). In multivariable analysis, the diffuse type was associated with shorter survival (diffuse versus intestinal: hazard ratios 2.06, p = 0.006). A pathologically (near) complete response (TRG 1 or 2) was seen less frequently in diffuse type than in intestinal type carcinomas (24% versus 60%; p = 0.015).
Conclusions: Patients with diffuse type oesophageal adenocarcinomas had a significantly worse prognosis than those with intestinal type carcinomas. Intestinal type carcinomas showed a better response to neoadjuvant chemoradiotherapy than diffuse type carcinomas. These differences call for the exploration of differentiated approaches in the potentially curative treatment of oesophageal adenocarcinomas.
Keywords: Adenocarcinoma; Chemoradiotherapy; Diffuse; Histology; Laurén classification; Neoadjuvant treatment; Oesophageal neoplasms; Pathological response; Prognosis; Survival.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015. Dis Esophagus. 2017. PMID: 28475724
-
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?Eur J Surg Oncol. 2015 Oct;41(10):1333-9. doi: 10.1016/j.ejso.2015.05.012. Epub 2015 Jun 6. Eur J Surg Oncol. 2015. PMID: 26091848
-
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. Lancet Oncol. 2015. PMID: 26254683 Clinical Trial.
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. doi: 10.1016/j.athoracsur.2004.04.046. Ann Thorac Surg. 2004. PMID: 15464463 Review.
-
Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.Curr Oncol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11912-017-0559-8. Curr Oncol Rep. 2017. PMID: 28213876 Free PMC article. Review.
Cited by
-
The Prognostic Impact of Histology in Esophageal and Esophago-Gastric Junction Adenocarcinoma.Cancers (Basel). 2021 Oct 18;13(20):5211. doi: 10.3390/cancers13205211. Cancers (Basel). 2021. PMID: 34680360 Free PMC article.
-
Towards Personalization in the Curative Treatment of Gastric Cancer.Front Oncol. 2020 Nov 30;10:614907. doi: 10.3389/fonc.2020.614907. eCollection 2020. Front Oncol. 2020. PMID: 33330111 Free PMC article. Review.
-
Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.Cancers (Basel). 2021 Jan 14;13(2):290. doi: 10.3390/cancers13020290. Cancers (Basel). 2021. PMID: 33466779 Free PMC article.
-
Targeted Sequencing of Sorted Esophageal Adenocarcinoma Cells Unveils Known and Novel Mutations in the Separated Subpopulations.Clin Transl Gastroenterol. 2020 Sep;11(9):e00202. doi: 10.14309/ctg.0000000000000202. Clin Transl Gastroenterol. 2020. PMID: 33094962 Free PMC article.
-
Novel Histologic Categorization Based on Lauren Histotypes Conveys Prognostic Information for Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.Cancers (Basel). 2021 Mar 15;13(6):1303. doi: 10.3390/cancers13061303. Cancers (Basel). 2021. PMID: 33804009 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous